Jay Bradner, M.D., has revealed that Novartis has scrapped one-fifth of its drug programs. The cull is designed to limit Novartis’ pipeline to potentially transformative therapies that fit with the company’s ambitions.
Talking to Bloomberg, Novartis Institutes for Biomedical Research President Bradner shared top-line details of the results of a pipeline review. Novartis went into the review with 430 drug programs in its pipeline. It is exiting the review with 340 drug programs. Some of the scrapped drugs will languish at Novartis. Others may be licensed out.
Novartis has yet to share details of the programs affected by the cull. But Bradner did provide insights into the thinking that led Novartis to identify pipeline prospects as surplus to requirements.
“The sadness about these 90 projects is there’s some great science there,” Bradner said. “These are not bad ideas. Many of them have momentum, but they either are not likely to be transformative for patients, or are ill-suited to the focused business ambitions of Novartis.”
Novartis’ recent third-quarter results featured some news of drug program comings and goings but nothing on the scale of the cuts outlined by Bradner. More details may emerge at the R&D update event Novartis is holding in London on Monday.
Whatever the identities of the drugs on the block, the contours of the results of the pipeline review are familiar. As happened at GlaxoSmithKline following the appointment of Emma Walmsley as CEO, the arrival of a new leader at Novartis has triggered a cull of pipeline programs. Over the past two years, Alexion, Biogen and Eli Lilly have been through similar post-leadership change reviews.
The scale of the cull sets Novartis’ actions apart, though. GSK decided to scrap or offload 65 drug programs in the 15 months after Walmsley’s appointment. Novartis, a bigger company, has decided to drop 90 programs within nine months of Vas Narasimhan taking over.
By Nick Paul Taylor
Source: Fierce Biotech
Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.
Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.
The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).
